AMYLOIDOSIS ALLIANCE The Voice of Patients

Research

Clinical trials

Every amyloidosis study now recruiting, about to open, or enrolling by invitation, anywhere in the world, listed straight from ClinicalTrials.gov and refreshed every day.

Information, not medical advice. The Alliance does not run these studies and cannot enrol you in one. If a trial looks relevant, discuss it with the doctor who follows your amyloidosis.

Recruiting and upcoming studies

The list covers AL, ATTR and AA amyloidosis as well as cerebral amyloid angiopathy. Each card says where the study stands: open to anyone who meets its criteria, not yet open, or restricted to people the investigators invite. Studies that close simply leave the list.

Showing 37–48 of 208 trials

Not yet recruitingAL (light chain)

Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis (opens on ClinicalTrials.gov)

Amyloid light chain (AL) amyloidosis is a rare disease caused by abnormal plasma cells producing misfolded light chain proteins that deposit in organs, leading…

Study
Interventional (treatment)
Phase
Phase 3
Sponsor
AbbVie

No study locations listed yet

NCT07793422Updated 28 August 2026

RecruitingNot specified

Ultrasound Therapy In Cardiac Amyloidosis (opens on ClinicalTrials.gov)

This is a prospective pilot clinical study of subjects with cardiac amyloidosis and control subjects without amyloidosis where we plan to evaluate changes in…

Study
Interventional (treatment)
Phase
Phase 4
Sponsor
Brigham and Women's Hospital

Recruiting in: United States

NCT04667494Updated 21 August 2026

RecruitingAL (light chain)

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) (opens on ClinicalTrials.gov)

This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned…

Study
Interventional (treatment)
Phase
Phase 1
Sponsor
Regeneron Pharmaceuticals

Recruiting in: GreeceSouth KoreaSpainTaiwan+2

NCT06292780Updated 18 August 2026

Enrolling by invitationNot specified

PET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis (opens on ClinicalTrials.gov)

This observational study will evaluate the imaging performance of the investigational positron emission tomography (PET) radiotracer[18F]Fluselenamyl (FSA) in individuals with cardiac amyloidosis. The study…

Study
Interventional (treatment)
Phase
Phase 1
Sponsor
Washington University School of Medicine

Recruiting in: United States

NCT07771621Updated 18 August 2026

Enrolling by invitationATTR (transthyretin)

Prospective Evaluation of Artificial Intelligence-enabled Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) (opens on ClinicalTrials.gov)

The TRACE-AI Diagnostic Study will evaluate the performance of artificial intelligence (AI) models applied to electrocardiograms (AI-ECG) and echocardiograms (AI-Echo) to identify transthyretin amyloid…

Study
Observational (registry, imaging)
Sponsor
Yale University

Recruiting in: United States

NCT07398950Updated 18 August 2026

This list only covers amyloidosis studies that are open or about to open. The registry holds every study, including those already completed.

Search all studies on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov (U.S. National Library of Medicine). List last retrieved on 25 September 2026. clinicaltrials.gov

Not sure where to start?

Our member associations know the teams running these studies in their own country, and can help you prepare the conversation with your doctor.

Find an association near you
Contact the Alliance